One of the biggest differentiators for Inceptor Bio is our vision for a unique shared state-of-the-art manufacturing concept, which is central to our strategy. The Advanced Manufacturing Platform (AMP+) is a cell and gene therapy good manufacturing practices (GMP) infrastructure that will be shared by the Inceptor Bio family of companies.
Our team’s experience in cell and gene therapy manufacturing technologies and processes is unparalleled, as the group includes some of the leading pioneers in the space. Our vision for the AMP+ is to provide the infrastructure and flexibility to advance a diverse range of cell and gene therapy technologies with a dedicated and passionate team. Whether it is CAR-T, CAR-NK, CAR-M, lentiviral vectors, AAVs, or others, the AMP+ provides access to the essential capability of early-stage clinical manufacturing.
Enhanced Speed & Timelines
Operational Flexibility & Control
In-House Process & Manufacturing Expertise
Strategic & Enterprise Value
Optimized Multi-Platform Costs
Our experienced staff will run the state-of-the-art facility and the quality system, enabling our Inceptor Bio family of companies to drive corporate goals forward knowing the quality, cost, and speed of clinical manufacturing are optimized for maximal benefit and value.
While more manufacturing capacity in cell and gene therapy has been coming online rapidly over the past five years, access to manufacturing for Phase I and II clinical materials remains scarce. This limited availability promotes high costs, long lead times, and adds unnecessary risk to the development projects. By addressing the struggles inherent in safely bringing a drug to market, Inceptor Bio’s AMP+ will deliver a unique approach and capability that delivers powerful solutions for optimizing new therapy development.